Peritonitis secondary prevention: Difference between revisions

Jump to navigation Jump to search
m (Formatting)
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Peritonitis}}
{{Peritonitis}}
{{CMG}}  
{{CMG}} {{AE}} {{SCh}}
 
{{PleaseHelp}}
 
==Overview==
==Overview==


==Secondary Prevention==
==Secondary Prevention==
*PBP has a high rate of recurrence.
*Up to 70% of patients experience a recurrence within 1 year.
*Antibiotic prophylaxis is recommended for patients with a history of PBP to reduce this rate to <20% and improve short-term survival rates.
*Prophylactic regimens for adults with normal renal function include
fluoroquinolones (ciprofloxacin, 750 mg weekly; norfloxacin, 400 mg/d) or
trimethoprim-sulfamethoxazole (one double-strength tablet daily).
*However, long-term administration of broad-spectrum antibiotics has been shown to increase the risk of severe infections by multi-drug resistant organisms.


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
[[Category:Needs content]]
[[Category:Gastroenterology]]
[[Category:Surgery]]
[[Category:Emergency medicine]]
[[Category:Infectious disease]]
{{WS}}
{{WS}}
{{WH}}
{{WH}}

Latest revision as of 19:49, 12 January 2017

Peritonitis Main Page

Patient Information

Overview

Causes

Classification

Spontaneous Bacterial Peritonitis
Secondary Peritonitis

Differential Diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shivani Chaparala M.B.B.S [2]

Overview

Secondary Prevention

  • PBP has a high rate of recurrence.
  • Up to 70% of patients experience a recurrence within 1 year.
  • Antibiotic prophylaxis is recommended for patients with a history of PBP to reduce this rate to <20% and improve short-term survival rates.
  • Prophylactic regimens for adults with normal renal function include
fluoroquinolones (ciprofloxacin, 750 mg weekly; norfloxacin, 400 mg/d) or 
trimethoprim-sulfamethoxazole (one double-strength tablet daily). 
  • However, long-term administration of broad-spectrum antibiotics has been shown to increase the risk of severe infections by multi-drug resistant organisms.

References

Template:WS Template:WH